Skip to content

ELOXX PHARMACEUTICALS, INC.: 10-Q filed 2016-02-16

What ELOXX PHARMACEUTICALS, INC. reported in its quarterly report filed 2016-02-16 (fiscal Q2 2016): 24 published measures, 64 facts as tagged in accession 0001144204-16-082378.

This filing

Form
10-Q (quarterly report)
Filed
2016-02-16
Fiscal period
fiscal Q2 2016
Accession
0001144204-16-082378 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ELOXX PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2015-12-3115,643,954USD
At 2015-06-3019,547,395USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2015-12-316,919,375USD
At 2015-06-307,322,601USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2015-12-318,724,579USD
At 2015-06-3012,224,794USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2015-12-312,366,573USD
At 2015-06-303,334,626USD
At 2014-12-312,107,452USD
At 2014-06-306,111,340USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2015-10-01 to 2015-12-31-3,855,420USD92
2015-07-01 to 2015-12-31-4,036,163USD184
2014-10-01 to 2014-12-31-10,746,127USD92
2014-07-01 to 2014-12-31-15,929,934USD184

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

PeriodValueUnitDays
2015-07-01 to 2015-12-310USD184
2014-07-01 to 2014-12-31111,045USD184

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

PeriodValueUnitDays
At 2015-12-31124,299USD
At 2015-06-30185,948USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2015-10-01 to 2015-12-3164,357USD92
2015-07-01 to 2015-12-3188,833USD184
2014-10-01 to 2014-12-31240,038USD92
2014-07-01 to 2014-12-31379,171USD184

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2015-10-01 to 2015-12-31-3,758,106USD92
2015-07-01 to 2015-12-31-4,909,462USD184
2014-10-01 to 2014-12-31-10,747,122USD92
2014-07-01 to 2014-12-31-15,932,714USD184

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2015-12-312,687,934USD
At 2015-06-303,729,726USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2015-12-31569,155USD
At 2015-06-30778,516USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2015-12-3163,504USD
At 2015-06-30232,033USD

Goodwill carrying amount

Recognized goodwill remaining after accumulated impairment. It arises from business combinations and does not measure the current value of the company’s brand.

PeriodValueUnitDays
At 2015-12-312,980,951USD
At 2015-06-305,780,951USD

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2015-10-01 to 2015-12-31594,504USD92
2015-07-01 to 2015-12-311,196,087USD184
2014-10-01 to 2014-12-311,371,930USD92
2014-07-01 to 2014-12-313,492,086USD184

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2015-12-3120,420,608shares
At 2015-06-3018,752,813shares

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2015-12-31119,899,641USD
At 2015-06-30119,217,880USD

Other noncurrent liabilities

Noncurrent liabilities the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2015-12-3199,728USD
At 2015-06-30122,038USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

PeriodValueUnitDays
At 2015-12-31450,929USD
At 2015-06-30408,705USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2015-12-31321,361USD
At 2015-06-30395,100USD

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2015-10-01 to 2015-12-31-3,869,534USD92
2015-07-01 to 2015-12-31-4,198,646USD184
2014-10-01 to 2014-12-31-10,763,849USD92
2014-07-01 to 2014-12-31-15,962,156USD184

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

PeriodValueUnitDays
2015-10-01 to 2015-12-31-3,869,534USD92
2015-07-01 to 2015-12-31-4,198,646USD184
2014-10-01 to 2014-12-31-10,763,849USD92
2014-07-01 to 2014-12-31-15,962,156USD184

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2015-10-01 to 2015-12-31401,102USD92
2015-07-01 to 2015-12-31988,375USD184
2014-10-01 to 2014-12-311,253,226USD92
2014-07-01 to 2014-12-312,027,826USD184

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2015-07-01 to 2015-12-310USD184
2014-07-01 to 2014-12-31160,782USD184

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2015-07-01 to 2015-12-31-168,529USD184
2014-07-01 to 2014-12-31404,061USD184

Inspect the source

Entity
ELOXX PHARMACEUTICALS, INC. / CIK 0001035354
Captured
2026-09-20T05:15:09.498Z
SEC response SHA-256
b351a9ed06ee3e6f1d738bbdb3852b866526fe561e11a7ffd4a81bc43bb27195

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001035354.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))